Interview: Why Europe’s Biotech ‘Prime Time’ Is Now
VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch
Executive Summary
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
You may also be interested in...
Woodford Debacle Is A Test Of UK Biotech’s Resilience
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.